杭州博之锐生物制药有限公司
Clinical Trials
0
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
8
NMPA:8
Drug Approvals
Recombinant Human Tumor Necrosis Factor-α Receptor II:IgG Fc Fusion Protein Injection
- Product Name
- 重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白注射液
- Approval Number
- 国药准字S20250003
- Approval Date
- Jan 8, 2025
NMPA
Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection
- Product Name
- 注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白
- Approval Number
- 国药准字S20150005
- Approval Date
- Sep 3, 2024
NMPA
Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein for Injection
- Product Name
- 注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白
- Approval Number
- 国药准字S20150006
- Approval Date
- Jul 24, 2024
NMPA
Tofacitinib Citrate Tablets
- Product Name
- 枸橼酸托法替布片
- Approval Number
- 国药准字H20213263
- Approval Date
- Apr 13, 2021
NMPA
Adalimumab Solution for Injection
- Product Name
- 安健宁
- Approval Number
- 国药准字S20190043
- Approval Date
- Dec 6, 2019
NMPA
Clinical Trials
No trials found
News
No news found